<DOC>
	<DOCNO>NCT01733147</DOCNO>
	<brief_summary>Will oral supplementation Omega 3 free fatty acid obese Barrett 's esophagus subject downregulate pro-neoplastic pro-inflammatory pathway esophagus anti-inflammatory pathway ?</brief_summary>
	<brief_title>Modulation Esophageal Inflammation Barrett 's Esophagus Omega-3 Fatty Acids</brief_title>
	<detailed_description />
	<mesh_term>Inflammation</mesh_term>
	<mesh_term>Barrett Esophagus</mesh_term>
	<criteria>Inclusion Criteria Presence BE define ≥ 1 cm visible columnar mucosa distal esophagus intestinal metaplasia histology . Absence high grade dysplasia EAC baseline histology . BMI &gt; 30 kg/m2 waist circumference &gt; 102 cm men , &gt; 88 cm woman . Ability give inform consent . Exclusion Criteria Allergy ω3 FFAs , fish shellfish . Presence high grade dysplasia cancer histology . Pregnant breastfeed woman Presence esophagitis initial endoscopy symptom refractory GERD ( heartburn regurgitation ≥ 2 time week ) indicative uncontrolled gastroesophageal reflux . Inability give inform consent . Currently take Omega3 FFA prescription . Anticoagulant therapy ( Plavix , Warfarin , Coumadin ) AST ALT level &gt; three time upper limit normal baseline LDL &gt; 200 mg/dl baseline . INR &gt; 2</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Barrett 's esophagus</keyword>
	<keyword>Obesity</keyword>
	<keyword>Omega-3 fatty acid</keyword>
</DOC>